Immune Checkpoint Inhibitors in Cancer

• Author : Fumito Ito,Marc Ernstoff
• Publisher : Elsevier Health Sciences
• Release Date : 2018-09-03
• ISBN : 9780323549509

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It’s an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how

• Author : Anonim
• Publisher : Unknown
• Release Date : 2022-12-01
• ISBN : OCLC:1125727614

• Author : Jie Xu
• Publisher : Springer Nature
• Release Date : 2020-03-17
• ISBN : 9789811532665

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not

• Author : Marc S. Ernstoff, MD,Igor Puzanov, MD, MSCI, FACP,Caroline Robert, MD, PhD,Adi M. Diab, MD,Peter M. Hersey, MD, PhD
• Publisher : Springer Publishing Company
• Release Date : 2019-03-15
• ISBN : 9780826172150

The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured

• Author : Hilal Arnouk,Bassam Abdul Rasool Hassan
• Publisher : Unknown
• Release Date : 2021
• ISBN : 1839688696

Recent advances in precision medicine and immuno-oncology have led to highly specific and efficacious cancer therapies such as monoclonal antibodies and immune checkpoint inhibitors (ICIs). This book provides an up-to-date overview of advances in the field of immuno-oncology. Chapters cover such topics as ICIs and how they mount a robust immune response against cancer cells as well as the response of ICIs to treatment predictive biomarkers and their potential immune-related adverse events (irAEs). Additionally, the book includes a comprehensive review

• Author : Tim F. Greten
• Publisher : Springer
• Release Date : 2017-10-04
• ISBN : 9783319649580

In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of

• Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
• Publisher : National Academies Press
• Release Date : 2019-09-05
• ISBN : 9780309490894

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g.,

• Author : National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum
• Publisher : National Academies Press
• Release Date : 2019-10-05
• ISBN : 9780309490863

In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g.,

• Author : Martin D. Abeloff,James O. Armitage,John E. Niederhuber,Michael B. Kastan,W. Gillies McKenna
• Publisher : Elsevier Health Sciences
• Release Date : 2008-06-30
• ISBN : 9781437720563

Carrying on the tradition established by its founding editor, the late Dr. Martin Abeloff, the 4th Edition of this respected reference synthesizes all of the latest oncology knowledge in one practical, clinically focused, easy-to-use volume. It incorporates basic science, pathology, diagnosis, management, outcomes, rehabilitation, and prevention – all in one convenient resource – equipping you to overcome your toughest clinical challenges. What's more, you can access the complete contents of this Expert Consult title online, and tap into its unparalleled guidance wherever

• Author : Yago Pico de Coaña
• Publisher : Humana Press
• Release Date : 2019-01-22
• ISBN : 1493989782

This detailed volume describes a series of techniques that are essential for evaluating the efficacy of new checkpoint blockade therapies as well as understanding the mechanisms behind the therapies that have already been approved. Beginning with a section on describing the tumor microenvironment and evaluating the immune system at a systemic level, the book continues by covering functional assays that provide answers to questions that may be raised after studying the immune system and its responses to immunotherapies, as well

• Author : Anonim
• Publisher : Demos Medical Publishing
• Release Date : 2010-03-08
• ISBN : 1935281801

Thoracic Malignancies: Thoracic Malignancies is the first title in Radiation Medicine Rounds. These tumors take more lives than any others and they are among the most preventable of tumors. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Thoracic Malignancies addresses the multi-disciplinary nature of the care of these tumors. There is representation from radiation oncology, medical oncology, and surgery ensuring a well-rounded summarization of current practice. Included are chapters on lung

• Author : Institute of Medicine,Committee on Approaching Death: Addressing Key End-of-Life Issues
• Publisher : National Academies Press
• Release Date : 2015-03-19
• ISBN : 9780309303132

For patients and their loved ones, no care decisions are more profound than those made near the end of life. Unfortunately, the experience of dying in the United States is often characterized by fragmented care, inadequate treatment of distressing symptoms, frequent transitions among care settings, and enormous care responsibilities for families. According to this report, the current health care system of rendering more intensive services than are necessary and desired by patients, and the lack of coordination among programs increases

• Author : S. Clarke,B.T. Li
• Publisher : Karger Medical and Scientific Publishers
• Release Date : 2021-06-29
• ISBN : 9783318068221

The treatment of cancer has been revolutionized by therapies that modulate the immune system, with benefits for quality of life and survival. Standards of care have changed to reflect developments, but the area is moving fast. Keeping abreast of new therapies and trial data can be challenging. This second edition of 'Fast Facts: Immuno-Oncology' takes you from the fundamentals of immunology through to the new concepts of immunoediting and immunotherapy and likely future directions. Whether you have worked in oncology

• Author : Andrea Necchi,Philippe E. Spiess
• Publisher : Springer Nature
• Release Date : 2022-01-03
• ISBN : 9783030805463

This book aims to provide readers with a current overview of enrolling trials with immune-checkpoint inhibitors in the preoperative setting of localized bladder cancer, renal cell carcinoma, and prostate cancer. The advent of immunotherapy has revolutionized treatments of genitourinary malignancy and evolved strategies for multidisciplinary management. This book explains neoadjuvant checkpoint inhibitors in localized genitourinary cancers, providing insights into the mechanisms of response and development of resistance of cancer cells to immunotherapy. It debates optimal trial design of preoperative checkpoint

• Author : Haidong Dong,Svetomir N. Markovic
• Publisher : Springer
• Release Date : 2018-01-05
• ISBN : 9783319706221

This book provides patients and their physicians (especially “non-oncologist” health care providers) with a clear and concise introduction to cancer immunotherapy, which, unlike traditional forms of cancer therapy, acts by boosting the patient’s own immune system to fight cancer. The unique features of cancer immunotherapy make its management, monitoring and side-effects different from those of traditional cancer therapy. Especially novel are the side effects of cancer immunotherapy, necessitating greater awareness for both patients and physicians in order to minimize